GSE Ultra 110™ can prevent free-radical damage to collagen and elastin, push back the clock, and reverse the effects of aging on your body.* GSE Ultra 110™ is a super-antioxidant providing 50 times more antioxidant protection than Vitamin E and 20 times more protection than Vitamin C. Oligomeric Proanthocyanidin Complexes (OPC), the super-antioxidants in GSE Ultra 110™, are the most active and bioavailable of all the antioxidants.
To a large extent, youthfulness is determined by the suppleness of your collagen and elastin. Your skin, blood vessels, joints and every membrane within your body are laced together with these connective tissue components.
During infancy, these connective tissues are extremely soft and pliable. Over time the collagen and elastin fibers gradually become cross-linked by free radical damage. As this happens, your skin becomes leathery and wrinkled. Your arteries lose their elasticity and become hardened. Your joints and cartilage stiffen. The lens of your eye becomes cross-linked and clouded. Your spine becomes stiff and bent. Even the neurons of your brain become entangled and damaged. In short every part of your body gradually deteriorates.
You can fight back. When taken orally, GSE Ultra 110™ is rapidly absorbed into the blood stream and distributed to the connective tissue where it fights free radical damage, inhibits collagen destroying enzymes, promotes new collagen and elastin formation and slows or even reverses the biological process of aging.
By protecting, restoring and strengthening the collagen and elastin fibers throughout the body, GSE Ultra 110™can reduce the unsightly appearance of varicose veins, the tendency to easy bruising, swelling of the legs, aching pains and stiffness of the joints and hardening of the arteries.
GSE Ultra 110™ is the most potent preventive medicine that you can take. If you want to reverse the aging process and look and feel young again, you should try GSE Ultra 110..
The OPC’s in GSE Ultra 110™ strengthens the heart, stomach and intestinal linings, sinus and respiratory membranes and skin and joint tissues. It inhibits destructive enzymes, reduces excessive histamine release, which constricts blood vessels, and prevents its production. It inhibits blood cells from coming together and becoming thick and “sticky”, improves capillary blood vessel resistance and reduces capillary leakage, reduces accumulation of fluid in cells and tissues, possesses anti-inflammatory activity, enhances Interleukin-2 production and increases Natural Killer Cell activity, strengthening the immune system. Gallic Acid found in grape seeds has been shown to possess anti-inflammatory activity and to aid in killing cancer cells, while selectively sparing normal cells.
GSE Ultra 110™ contains the highest concentration of the most active, water-soluble Grape Seed Extract available in the world. Other brands may contain higher percentage of OPC, but yield much smaller quantities of effective OPC.
GSE Ultra 110™ also contains a highly standardized Grape Skin Extract, containing Resveretrol, which has been shown to block the initiation, promotion and progression of any substance that promotes cancer cells.
GSE Ultra110™ Two Capsules Contain
Vitamin C (Ascorbic Acid) 250mg
Leucoselect® Grape Seed Extract(98-100% Total Polyphenols;80-85% Proanthocyanidins (OPC)
110 mg
Grape Skin Extract (24% Total Polyphenols5% Anthocyanin, 150ppm Reservatrol)
110 mg
Suggested Use:
Take one or two capsules, two or three times per day as a dietary supplement, or as directed by your healthcare provider.
GSE Ultra110™ – Grape Seed Extract: UPC Code #: 7-30610-01001-3
*The claims have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
GSE Ultra 110 Grape Seed Extract
Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.
The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.
This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).
Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.
The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.
At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):
✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)
Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.
The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.
Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.
Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.
Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.
This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.
The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”
